Is Lamb’s Blood an Antivenom for Snake Bites?

Raw lamb’s blood does not neutralize snake venom when applied to a bite wound or swallowed. No peer-reviewed study has ever found that unprocessed blood from a lamb, sheep, or goat counteracts envenomation in any clinically meaningful way. The belief persists in several folk-medicine traditions, and it contains a misleading grain of truth: sheep are one of the animals pharmaceutical companies immunize against snake venom to produce real, clinically tested antivenom. But the gap between a living sheep that has been vaccinated against venom and a cup of raw lamb’s blood at a snakebite scene is enormous, spanning industrial purification, concentration, and intravenous delivery that no folk remedy replicates.

Where the Belief Comes From

Animal-based folk remedies for snakebite have deep roots in many cultures. In parts of Latin America, hundreds of animal species have been catalogued as ingredients in traditional medicine, including the blood, organs, and skins of livestock. In rural Brazilian communities, before antivenom became available, people relied on charms, prayers, and homemade remedies to treat or protect against snake bites.¹ Similar traditions appear across Africa, the Middle East, and South Asia, where goat and sheep products have been applied to bite wounds for generations.

The specific idea that lamb’s blood works against venom likely draws on two overlapping sources. First, sheep have long been valued in pastoral communities, and their blood carries spiritual and medicinal symbolism in multiple religious and cultural traditions. Second, word of antivenom production using sheep may have filtered into communities in a distorted form. If scientists are extracting something from sheep blood that fights venom, the reasoning goes, the blood itself must be the cure. That reasoning skips the most important part of the process.

How Sheep Actually Contribute to Real Antivenom

Pharmaceutical antivenom production does use sheep, but the process looks nothing like folk application. In a typical protocol, a flock of sheep is immunized with carefully measured doses of snake venom over weeks or months. The animals’ immune systems respond by generating antibodies that bind to and neutralize the toxic components in the venom. In one study, researchers immunized 25 sheep with a mixture of venoms from four European adder species and found that all 25 animals responded quickly and maintained high levels of specific antibodies for the entire two-year study period.²

But the antibodies circulating in those sheep are not the finished product. After blood is drawn, the plasma is separated and the antibodies are extracted. In some manufacturing processes, the whole antibody molecule is further broken down into smaller fragments, such as Fab or F(ab’)₂ pieces, which are better at reaching tissues where venom has spread. One production method uses an enzyme called papain to digest anti-cobra-venom plasma into Fab fragments, followed by multiple purification steps to remove everything that is not a useful antibody fragment.³ The result is a sterile, concentrated pharmaceutical delivered intravenously under medical supervision. Nothing about that resembles smearing blood on a wound.

Why Raw Blood Cannot Substitute for Processed Antivenom

Even if you could somehow obtain blood from a sheep that had been immunized against the exact species of snake that bit you, drinking or applying that blood would not help. The reasons are straightforward.

First, the concentration of relevant antibodies in whole blood is far too low. Manufacturing antivenom involves purifying and concentrating the antibodies many times over from large volumes of plasma. A few tablespoons of raw blood contain a negligible fraction of what a single clinical dose requires. Second, antibodies are proteins. If swallowed, they are broken down by stomach acid and digestive enzymes before they can reach the bloodstream. They would never arrive at the bite site in functional form. Third, even when antivenom is delivered the correct way, through an IV line, the pharmacokinetics matter enormously. Fab fragments distribute widely through the body’s tissues and are cleared relatively quickly through the kidneys, while intact antibody molecules circulate longer but distribute more slowly.⁴ Getting the timing and dosing right is a clinical challenge even with pharmaceutical-grade products. Raw blood provides no control over any of these variables.

And most lambs and sheep at a slaughterhouse or farm have never been immunized against snake venom at all. Their blood contains no relevant antibodies in the first place. The folk remedy, in practical terms, is applying a biologically inert fluid to a wound while venom continues to spread.

The Real Dangers of Animal-Product Folk Treatments

Applying raw animal products to a snake bite wound does not just fail to help. It can cause serious secondary harm. A case report described a 35-year-old woman in Afghanistan who was bitten by a snake and treated traditionally by having raw goat skin applied directly to the wound. The goat skin, obtained from a slaughterhouse, introduced bacterial spores into the wound, and the woman developed wound botulism, a potentially fatal condition marked by progressive paralysis.⁵ She survived only because she eventually received medical treatment with botulinum antitoxin, but the traditional remedy added a second life-threatening illness on top of the envenomation.

Raw animal blood carries its own infection risks. It can harbor bacteria, parasites, and viruses that thrive when introduced into a puncture wound. The warm, moist, tissue-damaged environment of a snakebite is an ideal incubation site for pathogens.

Perhaps the most dangerous aspect of folk remedies, though, is the delay they cause. A systematic review of pre-hospital snakebite treatment found that most traditional practices are applied by traditional healers who may be preferred over healthcare professionals as a first step. That preference can delay arrival at a medical facility, and research in northeastern Nigeria showed that the odds of dying from snakebite increased by about one percent for every hour of delay in reaching a healthcare facility.⁶ When someone is applying lamb’s blood to a bite wound, they are not in an ambulance. Every minute spent on an ineffective remedy is a minute of venom spreading unchecked.

Tourniquets, Incisions, and Other Persistent Myths

Lamb’s blood is not the only folk remedy that refuses to die. A review of studies published between 1947 and 2023 found that harmful pre-hospital interventions remain widespread among snakebite victims globally. The most common was the application of tourniquets, used by roughly 46 percent of patients across the studies reviewed. Cuts and incisions at the bite site accounted for about 7 percent of cases, and applying various natural or synthetic substances to the wound for about 6 percent.⁷ Ingestion of herbal remedies made up another 3 percent.

Tourniquets can trap venom in a limb and cause tissue death if left on too long. Cutting into the wound increases bleeding and infection risk without removing meaningful amounts of venom. Sucking venom from a bite, whether by mouth or commercial suction device, has been shown to extract negligible quantities. The consistent finding across decades of research is that none of these measures improve outcomes, and several make them worse. The only first-aid steps supported by evidence are immobilizing the bitten limb, keeping the person calm and still, removing jewelry or tight clothing before swelling starts, and getting to a hospital as fast as possible.

Sheep-Derived Versus Horse-Derived Antivenoms

In actual antivenom manufacturing, both horses and sheep are used as antibody donors, and the choice between them is a real question in toxicology. Most of the world’s antivenoms are still produced in horses, but sheep-derived (ovine) products have carved out an important role.

When researchers compared ovine antivenoms to commercial horse-derived antivenoms against several snake species, the sheep-derived antibodies were more effective at preventing lethal toxicity in laboratory tests for certain venoms, including South American rattlesnake venom. The ovine antibodies also performed better at inhibiting specific pharmacological effects of venom, such as the disruption of blood clotting and the destruction of red blood cells.⁸ In the United States, one of the two FDA-approved antivenoms for pit viper bites (CroFab) is manufactured from sheep, while the other (Anavip) is produced in horses. A retrospective study of rattlesnake envenomation in Arizona found that about 35 percent of CroFab-treated patients met criteria for full recovery at 14 days, compared with about 25 percent of Anavip-treated patients.⁹

The performance difference is partly about the antibody format. CroFab uses Fab fragments, which are small and distribute quickly through the body to reach venom in tissues. But that speed comes with a trade-off: Fab fragments are also cleared from the body faster than larger antibody formats. In some patients, venom effects recur after treatment because the Fab antivenom is eliminated from the body before it has neutralized all the venom. This mismatch, where the antivenom disappears faster than the venom does, is a recognized clinical challenge with Fab-based products.¹⁰ Anavip, which uses larger F(ab’)₂ fragments from horse plasma, stays in the body longer and may reduce the risk of recurrence, though it distributes to tissues more slowly.

Why Snake Venom Is So Difficult to Neutralize

Part of the reason folk remedies seem plausible to people who use them is that the mechanics of envenomation are invisible. Snake venom is not a single poison. It is a cocktail of dozens to hundreds of different proteins and peptides, each attacking the body through a different mechanism. Major classes include cytotoxins that destroy cells and tissues at the bite site, phospholipase enzymes that break down the membranes of cells, and metalloproteinases that degrade structural proteins and disrupt blood clotting.¹¹ Some venoms also contain neurotoxins that block communication between nerves and muscles, leading to paralysis.

Neutralizing this complex mixture requires antibodies that recognize and bind to many different toxin components simultaneously. This is why antivenom production involves immunizing animals with the actual venom: the animal’s immune system generates a diverse repertoire of antibodies against the many proteins in the mix. Even then, the antibodies generated against one snake species may not work against another. One experimental study found that an antivenom raised against seven viper venoms could protect mice from lethal doses of several venoms, including some that were not in the original immunizing mixture.¹² But cross-protection is unreliable. An antivenom developed against one group of Asian pit vipers showed vastly different potency against related species from a different region, with cross-neutralization ranging across a wide spectrum depending on how closely the venoms matched.¹³

The specificity problem underscores just how far a generic folk remedy sits from what is actually needed. If a pharmaceutical antivenom made from immunized animals and targeted at a specific group of snakes can still fall short against a related species, untreated blood from an unimmunized lamb has zero chance of doing anything useful.

Where Antivenom Research Is Headed

The limitations of traditional antivenom production, which depends on maintaining herds of immunized animals, harvesting their plasma, and enduring batch-to-batch variability, have pushed researchers toward alternatives that do not rely on animal blood at all. Monoclonal antibodies, engineered in labs rather than harvested from livestock, are being explored as a next-generation approach.¹⁴ These are single, precisely designed antibody molecules that can be produced in cell cultures at industrial scale without any animals involved.

One recent study used a synthetic human antibody library to develop an antibody that neutralizes a major class of neurotoxins produced by many medically important snakes. The antibody bound to diverse toxin variants with high affinity, blocked their interaction with nerve receptors in the lab, and protected mice from lethal venom doses. Structural analysis showed the antibody works by mimicking the shape of the receptor the toxin normally attaches to, essentially tricking the toxin into binding to a decoy.¹⁵ The researchers described the approach as a framework for building a universal antivenom from a cocktail of monoclonal antibodies, each targeting a different major toxin class.

Other groups are developing nanobody-based formats and small-molecule inhibitors that could be stored without refrigeration and potentially administered outside hospital settings.¹⁶ A heat-stable antivenom pill or auto-injector would be transformative in rural tropical regions where snakebite kills tens of thousands of people a year and cold-chain storage is unreliable. The irony is that these cutting-edge therapies are trying to solve the exact problem that folk remedies claim to have already solved: something simple you can use at the point of injury. The difference is that the lab-designed versions actually work, and their development is driven by a precise understanding of venom biochemistry rather than tradition and hope.